Introduction: Osteopenia/osteoporosis is a condition characterized by decrease in bone mineral density. It is a major public health problem especially for women in India. The clinical picture of osteopenia/osteoporosis is similar to the condition of Asthidhatukshaya described in Ayurveda which is characterized by the loss of saarata of Asthi dhatu leading to increased predisposition to other bone-related pathologies. Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti are some of the most common medicines used in the management of osteopenia/osteoporosis. However, safety data are not collected on these formulations.
INTRODUCTION
Osteopenia/osteoporosis is a condition characterized by decrease in bone mineral density. According to the estimates, out of the 230 million Indians expected to be over the age of 50 years in 2015, 20%, i.e., almost 46 million, are women with osteoporosis. Thus, osteoporosis is a major public health problem especially for women in India. 1 It is also one of the major risk factors for fractures, especially among elderly women. Osteoporosis is a silent disease until it is complicated by fractures that occur following minimal trauma or, in some cases, with no trauma. 2 Dietary changes, supplementation of Vitamin D and calcium, use of antiresorptive agents, and hormonal therapies along with exercise, regular monitoring of bone mineral density, and assessment of biomarkers related to bone tumor are advised in the management of this condition.
The clinical picture of osteopenia/osteoporosis is similar to the condition of Asthidhatukshaya described in Ayurveda, which is characterized by the gradual loss of quality (Saarata) of Asthi dhatu leading to increased predisposition to other bone-related pathologies. It happens due to the prakopa of Vata that occurs in Asthi. Prithvi 
MATERIALS AND METHODS
Open-label multicenter clinical trials were done in selected peripheral institutes of CCRAS to evaluate the safety and efficacy of Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti in osteopenia/ osteoporosis, and the details are briefed in Table 1 . Followup was done every 2 weeks to record the onset of any adverse reaction during the intervention.
The formulations fulfilling the physicochemical standards and quality parameters, and prepared as per standard operating procedures, were procured from good manufacturing practices-certified companies for all the studies. These two different clinical studies were approved by institutional ethics committee of all the participating centers and done in accordance with World Health Organization Good Clinical Practice guidelines. The data obtained from the completed clinical studies were analyzed retrospectively to assess the safety profile of the drugs through assessment of LFTs and KFTs. The data thus generated were analyzed to evaluate the safety of these formulations in the case of osteopenia/ osteoporosis.
Statistical Analysis
Laboratory parameters at the beginning and at the end of the trial period were compared using paired t-test. A p-value <0.05 was considered significant. All statistical analyses were performed using Statistical Package for the Social Sciences, version 15.0.
DRUG PROFILE
The ingredients of the formulations used in the two clinical trials are described in Tables 2 to 5 .
OBSERVATION AND RESULTS

Study I: Clinical Evaluation of Laksha Guggulu and Mukta-Shukti Pishti in the Management of Osteopenia/Osteoporosis
Among the total 88 patients who completed the trial, most of the patients, i.e., 71 (80.7%), were females and remaining 17 (19.3%) were males. Majority of the patients, 68 (77.3%), were literate and only 8 (9.1%) hailed from lower socioeconomic stratum. Maximum numbers of patients, i.e., 53 (60.2%), were housewives. Eighty-five (96.6%) were from urban population, and maximum number of patients, i.e., 41 (46.6%), followed a sedentary life. Maximum number of patients were of Pitta-kapha (66, 75%), followed by Vata-pitta prakriti (19, 21.6%). Asthisula was the major symptom present in 85 (96.5%) patients mostly along the dorsolumbar region (in 65.9% cases) of intermittent (51.1%) or continuous nature (45.5%). The symptom kesa loma pata was observed in 58 (65.9%) cases, and feeling of comfort with hot fomentation and local massage was observed in 68 (77.3%) cases. Serum bilirubin, SGPT, SGOT, serum ALP, serum protein, albumin, globulin, blood urea, and serum creatinine were within normal limits during the entire period. The values were compared with paired t-test after the trial and were found to be within the normal range. No significant adverse events could be identified due to drug during the study.
Study II: Clinical Evaluation of Ashwagandha Churna and Pravala Pishti in the Management of Osteopenia/Osteoporosis
Among the total 90 patients who completed the trial, 67 (74.4%) of the patients were females and remaining 23 (25.6%) were males. Majority of the patients (85, 94.4%) were literate and 20 (22.2%) were from lower socioeconomic stratum. Maximum numbers of patients (58, 64.4%) were housewives. Eighty-seven (96.7%) were urban from population. About 44 (48.9%) did moderate exercises, whereas 38 (42.2%) followed a sedentary life. Maximum number of patients were of Vata-pitta (38, 42.2%) followed by Pittakapha prakriti (35, 38.9%). Asthitoda was found to be the major symptom which was found in 87 (96.7%) followed by Shrama 79 (87.8%) and Sandhishaithilya 46 (51.1%). Serum bilirubin, SGPT, SGOT, serum ALP, serum protein, albumin, globulin, blood urea, and serum creatinine were within normal limits during the entire period, and the values were compared with paired t-test after the trial. The values were found to be within the normal range. No significant adverse events could be identified due to drug during the study.
The data regarding demographic profile, efficacy of safety obtained from both the studies are given in Tables 6 and 7 and Graphs 1 to 4. The pharmacological activity of Ashwagandha has been attributed to two main with anolides: with aniferin A and anolide. It has anti-stress and rejuvenating properties. 7 These drugs combined may act as Dhatuposhaka and Asthisandhanakara. Medical systems like Ayurveda have taken up the challenge to develop safe and effective remedies for their management. Both the interventions were found to be safe, and at the end of 84 days of intervention, no clinically significant changes were observed regarding various hematological parameters or in LFT or KFT. However, the analysis of the study results showed statistically highly significant reduction in the serum creatinine value in Laksha Guggulu and Mukta-Shukti Pishti group and significant reduction in SGPT value in Ashwagandha and Pravala Pishti group. Wherever statistically signifi- cant changes were observed regarding these parameters, the values were found to be within the clinically normal range. No adverse events or adverse reactions were noted during the trial period.
CONCLUSION
Evaluation of safety and efficacy of Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti was done through studies conducted at peripheral institutes of CCRAS spread throughout various biogeographical areas of India. The analysis of outcome of these scientifically planned studies demonstrates that in spite of the differences in gender, socioeconomic status, age group, Prakrati, and geographic region, Laksha Guggulu, Mukta-Shukti Pishti, Ashwagandha Churna, and Pravala Pishti proved to be safe in the management of osteopenia/ osteoporosis. No adverse reactions were noticed during the trial period.
